Oncolytics Biotech (NASDAQ:ONCY) Upgraded to “Moderate Buy” at Raymond James
Raymond James upgraded shares of Oncolytics Biotech (NASDAQ:ONCY – Free Report) to a moderate buy rating in a research report released on Thursday morning,Zacks.com reports. Raymond James also issued estimates for Oncolytics Biotech’s Q4 2024 earnings at ($0.09) EPS, FY2024 earnings at ($0.32) EPS, Q1 2025 earnings at ($0.09) EPS and FY2025 earnings at ($0.34) […]
More Stories
5N Plus Inc. (OTCMKTS:FPLSF) Sees Significant Decline in Short Interest
5N Plus Inc. (OTCMKTS:FPLSF – Get Free Report) saw a significant decrease in short interest in the month of October....
Lloyds Banking Group plc (NYSE:LYG) Short Interest Update
Lloyds Banking Group plc (NYSE:LYG – Get Free Report) saw a significant increase in short interest during the month of...
Short Interest in Jaguar Mining Inc. (OTCMKTS:JAGGF) Increases By 15.3%
Jaguar Mining Inc. (OTCMKTS:JAGGF – Get Free Report) was the recipient of a significant growth in short interest in the...
Short Interest in Fossil Group, Inc. 7% Senior Notes due 2026 (NASDAQ:FOSLL) Grows By 16.0%
Fossil Group, Inc. 7% Senior Notes due 2026 (NASDAQ:FOSLL – Get Free Report) was the target of a significant increase...
Humana Inc. (NYSE:HUM) Sees Large Growth in Short Interest
Humana Inc. (NYSE:HUM – Get Free Report) saw a significant increase in short interest in the month of October. As...
Stocks Sell Off at End of Week on Profit-Taking Ahead of Nvidia Earnings Report
By Panos Mourdoukoutas U.S. stocks ended the week with a sell-off due to profit-taking, rising bond yields, and disappointing earnings...